InsiderSignalSign in

← Insider buys

Braden Michael Leonard has bought stock on 32 days since Apr 2022

10% owner at Outset Medical, Inc., and 12 other companies

SEC CIK 0001373603 · Filings on SEC.gov ↗

$21.7MBought

$27.2MSold

Oct 5Last buy

Braden Michael Leonard's record

3 months after each buy, from the first price a copier could get.

−7.1%Average

−14.6 ptsVs S&P 500

4 of 17Higher

17 buys since 2022 with 3 months of prices.

Companies

Every filing

49 filings since Sep 2017, newest first

Outset Medical, Inc.

10% owner

$870K+9.7%Oct 5

Aclaris Therapeutics, Inc.

10% owner

$1.4M−2.0%Apr 27

Adverum Biotechnologies, Inc.

10% owner

$2.2M−20.0%Dec 5

Adverum Biotechnologies, Inc.

10% owner

$2.4M−18.0%Dec 3

Adverum Biotechnologies, Inc.

10% owner

$189K+1.0%Apr 28

Adverum Biotechnologies, Inc.

10% owner

$1.0M+12.0%Apr 24

Adverum Biotechnologies, Inc.

10% owner

$147K+1.0%Apr 2

Adverum Biotechnologies, Inc.

10% owner

$588K+2.0%Mar 20

Adverum Biotechnologies, Inc.

10% owner

$1.4M+14.0%Feb 28

Reneo Pharmaceuticals, Inc.

10% owner

$145K+2.0%Sep 26

Reneo Pharmaceuticals, Inc.

10% owner

$76K+1.0%Sep 19

Reneo Pharmaceuticals, Inc.

10% owner

$484K+9.0%Sep 16

Talis Biomedical Corp

10% owner

$44K+14.0%Sep 9

An2 Therapeutics, Inc.

10% owner

$1.6M+35.0%Aug 14

Reneo Pharmaceuticals, Inc.

10% owner

$381K+7.0%Aug 14

Aclaris Therapeutics, Inc.

10% owner

$473K+1.0%Aug 5

Aclaris Therapeutics, Inc.

10% owner

$359K+1.0%Jul 31

Adverum Biotechnologies, Inc.

10% owner

$613K+4.0%Jul 31

Aclaris Therapeutics, Inc.

10% owner

$202K+1.0%Jul 22

Adverum Biotechnologies, Inc.

10% owner

$1.8M+10.0%Jul 18

Aclaris Therapeutics, Inc.

10% owner

$406K+1.0%Jul 5

Aclaris Therapeutics, Inc.

10% owner

$1.7M+7.0%Jul 1

Aclaris Therapeutics, Inc.

10% owner

$628K+2.0%Jun 18

Aclaris Therapeutics, Inc.

10% owner

$1.8M+17.0%Jun 13

Reneo Pharmaceuticals, Inc.

10% owner

$640K+13.0%May 16

Avrobio, Inc.

10% owner

$971K+17.0%May 15

Imara Inc.

10% owner

$5.0M−38.0%Jan 5

Imara Inc.

10% owner

$5.0M−38.0%Jan 4

Imara Inc.

10% owner

$81K−1.0%Dec 30

Retractable Technologies Inc

10% owner

$4.8M−74.0%Dec 29

Imara Inc.

10% owner

$81K−1.0%Dec 29

Imara Inc.

10% owner

$203K−1.0%Dec 27

Astrotech Corp

10% owner

Retractable Technologies Inc

10% owner

$506K−6.0%Nov 30

Gemini Therapeutics, Inc. /de

10% owner

Astrotech Corp

10% owner

$157K+6.0%Sep 27

Astrotech Corp

10% owner

$117K+5.0%Sep 7

Astrotech Corp

10% owner

$219K+10.0%Aug 25

Imara Inc.

10% owner

$50K+1.0%May 18

Retractable Technologies Inc

10% owner

$554K+4.0%May 16

Retractable Technologies Inc

10% owner

$281K+2.0%May 11

Retractable Technologies Inc

10% owner

$1.6M+13.0%May 2

Imara Inc.

10% owner

$784K+21.0%Apr 25

Gemini Therapeutics, Inc. /de

10% owner

$1.3M+22.0%Apr 13

Prophase Labs, Inc.

10% owner

$3.9M−73.0%Oct 2

Build A Bear Workshop Inc

Former Director of the Issuer

$249K−2.0%Oct 2

Build A Bear Workshop Inc

Former Director of the Issuer

$430K−3.0%Sep 26

Build A Bear Workshop Inc

Former Director of the Issuer

$202K−1.0%Sep 21

Build A Bear Workshop Inc

Former Director of the Issuer

$720K−5.0%Sep 18

About Braden Michael Leonard

Leonard Braden Michael is a prominent investment manager and 10% owner of Aclaris Therapeutics Inc. (NASDAQ: ACRS), a healthcare company( He serves as the managing member of BML Capital Management, LLC, which functions as the general partner of BML Investment Partners, L.P., the investment vehicle through which he manages significant portfolio holdings( As of August 2024, Michael beneficially owns approximately 14.25 million shares of Aclaris Therapeutics worth over $50 million, representing a substantial stake in the biopharmaceutical company( Beyond Aclaris, Michael maintains significant investments in other therapeutic companies, including a 10% ownership position in AN2 Therapeutics and holdings in Cyteir Therapeutics Inc.(

Michael has been actively engaged in portfolio management across multiple healthcare and biomedical ventures. His investment strategy has historically favored acquisitions, with SEC Form 4 filings documenting seven purchase transactions in Aclaris over the past five years with no sales until recently( In April 2026, Michael's investment fund executed an open-market sale of 300,000 Aclaris shares at $4.53 per share, generating approximately $1.36 million( This transaction demonstrates his active management of portfolio positions while maintaining a significant long-term commitment to the healthcare sector through his various ownership stakes.

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.